EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSBMUG00000025917
Gene Symbol: KCNA5
3 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSBMUG00000009410
Gene Symbol: KCND3
3 Cross references
261 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 5

Ensembl ID : ENSBMUG00000021404
Gene Symbol: LOC102271011
2 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSBMUG00000017092
Gene Symbol: KCNQ2
3 Cross references
250 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSBMUG00000022697
Gene Symbol: KCNQ3
3 Cross references
193 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSBMUG00000009750
Gene Symbol: PSEN1
3 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSBMUG00000009285
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSBMUG00000017304
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme

Ensembl ID : ENSBMUG00000019200
Gene Symbol: LOC102287961
2 Cross references
305 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSBMUG00000004918
Gene Symbol: PTGDR
3 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBMUG00000015315
Gene Symbol: PTGDR2
1 Cross references
205 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSBMUG00000004113
Gene Symbol: PTGER2
3 Cross references
244 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).